Q2 2022 KEY INDICATORS
JAN-JUNE 2022 KEY INDICATORS
RECENT BUSINESS ACCOMPLISHMENTS
“Our second quarter results show development as we see the benefit of increased sales of our DSM proprietary medical products, as well as continued strong demand from international pharma and biotech companies for our pharmaceutical development and manufacturing services. I am pleased to see that the increased focus on DSM products is a contributing factor to financial performance in the first half of 2022, as this underpins that our underlying growth strategy is continuing to pay off,” says Justin Pierce, CEO of Magle Group.